We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




AI Tool Accurately Determines Breast Cancer Prognosis

By LabMedica International staff writers
Posted on 18 Jul 2025

A new study has found that cells and tissues surrounding a breast cancer tumor may hold critical information about how patients will respond to treatment. More...

The research, published in the journal Patterns, marks a significant step toward developing artificial intelligence (AI) tools to help oncologists more accurately determine prognoses and decide which treatments may be most effective on a case-by-case basis.

Researchers at Johns Hopkins University (Baltimore, MD, USA) have designed an interpretable machine learning model that analyzed images of microscopic tissues and biopsy samples from 579 breast cancer patients who were undergoing standard treatments such as chemotherapy. The model examined both the tumor and the surrounding tissue, assessing every cell’s position in relation to the tumor and interactions with neighboring cells. This allowed the algorithm to detect 66 unique cell patterns and categorize patients into seven prognostic groups based on these patterns. Unlike conventional AI methods, the model could clearly identify which specific elements contributed to each pattern, allowing researchers to reverse-engineer the data and uncover the driving factors behind the groupings.

The model’s validation revealed several significant findings. One group of patients with the best survival outcomes had a distinct combination of three cell types: CK8-18high, CXCL12high, and CK+CXCL12+. On the other hand, patients with self-aggregated HER2+ tumor cells had the worst outcomes—a result that aligns with the known aggressiveness of HER2-positive breast cancers. Additionally, triple-negative breast cancer patients with well-organized immune cells surrounding their tumors also had better prognoses than others with the same condition. These results suggest that analyzing spatial tissue patterns may provide oncologists with valuable biomarkers for predicting patient outcomes and personalizing treatment strategies. Moving forward, the researchers plan to expand their methodology to other imaging technologies and apply it to different types of cancer to uncover more actionable insights.

"We're developing a toolbox that you can use anytime you have a massive data set and you don't want to start with an explicit hypothesis," said first author Zhenzhen Wang, a PhD candidate in biomedical engineering at Johns Hopkins University. "Typically, you'd have to design a study to ask if one specific pattern of cells is important, and check if the answer is yes or no. But with our model, we can save time by asking open-ended questions about which patterns are important when trying to understand how patients will respond to treatment or have a better chance of survival."

Related Links:
Johns Hopkins University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.